Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Polatuzumab vedotin - Genentech

Next Previous
Drug Profile

Polatuzumab vedotin - Genentech

Alternative Names: ADC DCDS4501A; anti-CD79b-VC-MMAE; Antibody-Drug Conjugate DCDS4501A; DCDS-4501A; FCU-2711; polatuzumab vedotin-piic; polatuzumab vedotin-piiq; Polivy; RG-7596; RO-5541077; RO-5541077-000

Latest Information Update: 15 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; Roche; Weill Cornell Medical College
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diffuse large B cell lymphoma
  • Phase III Follicular lymphoma
  • Phase II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Richter's syndrome

Most Recent Events

  • 14 Dec 2023 Seagen has been acquired by Pfizer
  • 09 Dec 2023 Efficacy data from a phase III POLARIX trial in Diffuse large B cell lymphoma presented at the 65th American Society of Hematology Annual Meeting (ASH-Hem-2023)
  • 09 Dec 2023 Efficacy and adverse event data from a phase I trial in Diffuse large B cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition 2023 (ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top